Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Multicenter Study of Talabostat and Pemetrexed vs. Pemetrexed and Placebo in Patients With Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

NCT00290017 is registered in ClinicalTrials.gov with Point Therapeutics as lead sponsor.

NCT NCT00290017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00290017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Multicenter Study of Talabostat and Pemetrexed vs. Pemetrexed and Placebo in Patients With Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
Lead sponsor
Point Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2006
Completion date
Not reported
Enrollment
400 (estimated)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, lung cancer, neoplasms, lung, neoplasms, pulmonary